Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

d above, offset by the recording of $8.4 million in previously deferred expenses."In 2012, Auxilium accomplished a key goal of achieving full year profitability and we saw good overall commercial growth with both Testim and XIAFLEX, " said Adrian Adams, Chief Executive Officer and President of Auxilium.  "In 2013, we will continue to focus on financial discipline and commercial execution, in addition to preparing for the potential FDA approval and commercial launch of XIAFLEX for the treatment of Peyronie's disease in the fourth quarter, and further developing collagenase for the treatment of multiple potential indications."

Fourth Quarter 2012 and Recent Highlights:

  • In January 2013, the Company issued $350 million aggregate principal amount of 1.50% Convertible Senior Notes Due 2018 in a public offering.  The net proceeds from the offering, including the costs of related note hedge transactions, were approximately $310 million after deducting underwriters' discounts and commissions and estimated offering expenses. 
  • In January 2013, Auxilium expanded its exclusive license for XIAFLEX to include the potential treatment of cellulite as an additional indication for development.  In December 2012, Auxilium announced encouraging top-line 30-day data from the XIAFLEX phase Ib study in cellulite.
  • In December 2012, the U.S. Food and Drug Administration ("FDA") accepted the Company's supplemental Biologics License Application Filing for XIAFLEX for the treatment of Peyronie's Disease ("PD").  Under the Prescription Drug User Fee Act ("PDUFA"), the FDA is expected to take action on the application by September 6, 2013.
  • Fourth Quarter 2012 Financial Details  Total revenues for the three months ended December 31, 2012 were $172.5 compared to $73.3.million recorded in the fourth quarter of 2011.  This increase in net revenues was primarily due to revenue recognition of $93.6 million in deferred up-fr
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Auxilium Announces Appointments to Enhance Leadership Team
    2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
    6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
    7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
    8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
    (Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
    (Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
    (Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
    Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
    ... relying on existing telecommunications satellites, has put a second satellite ... weather information clients. , ,Last September, Loral Skynet ... and rerouted its customers to Telstar 5 and 6. The ... Birch, data services product manager for Weather Central, said his ...
    ... startups, biotech , ,Entrepreneurship, nanotechnology and biomedical engineering ... in Madison and Milwaukee, giving substance to what Wisconsin ... , , Tips for Entrepreneurs , ,Established entrepreneurs ... Entrepreneurs Conference , which runs June 1-2 at the ...
    ... MILWAUKEE Advocates of Windows and open-source software vied ... presentation of Wednesdays session of the ITEC conference in ... Labs , said that open-source software provides a technically ... companies that want a single, obvious place to turn ...
    Cached Biology Technology:Doyles Entrepreneurs and Research week nears 2Doyles Entrepreneurs and Research week nears 3Linux and Windows duke it out at ITEC 2Linux and Windows duke it out at ITEC 3
    (Date:1/22/2015)... , Europe,s most ... Patent Office to present a video retrospective of the most exciting ... Christofer Toumazou and Sophie Wilson   ... the Award   Starting on 22 January 2015 on   ...
    (Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
    (Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
    Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2
    ... 2013 -- American Associates, Ben-Gurion University of the Negev (AABGU) ... late Dr. Jordan Baruch, to fund stem cell research at ... The Jordan Baruch Stem Cell Research Fund was dedicated at ... Baruch and 20 members of her extended family. "Jordan ...
    ... new study has found that tamoxifen, a well-known breast ... mouse model of Duchenne muscular dystrophy (DMD). At present, ... the symptoms in boys with DMD, a debilitating muscular ... and cardiac impairments, paralysis, and premature death. This study ...
    ... TORONTO, Jan 14, 2013Taking a vitamin D supplement and drinking ... how much vitamin D is in a child,s body, new ... than even skin colour and exposure to the sun, according ... Michael,s Hospital. "Early childhood is a critical stage in ...
    Cached Biology News:Ben-Gurion U. establishes stem cell research fund in honor of inventor Jordan Baruch 2Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy 2Supplements and cow's milk play biggest roles in determining vitamin D levels in children 2
    ... for high-yield protein expression ,The ... a high-yielding clone of Sf9 cells. Pre-adapted ... Cell Medium, these cells are recommended for ... baculovirus infection or transfection of appropriate vectors. ...
    Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
    Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
    96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
    Biology Products: